McMahanet al[81] reported that obese db/db mice were treated with a dual FXR/TGR5 agonist (INT-767) for 6 weeks and the histologic features of NASH in these mice were significantly improved. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.